GSK goes hostile with $2.6 billion Human Genome offer

LONDON (Reuters) - GlaxoSmithKline will take its $2.6 billion bid for long-time partner Human Genome Sciences direct to shareholders this week, after its takeover offer was rejected last month by the…
Read the full story: Reuters: Health News